Literature DB >> 11267982

Antibodies to Epstein-Barr virus thymidine kinase: a characteristic marker for the serological detection of nasopharyngeal carcinoma.

Y Connolly1, E Littler, N Sun, X Chen, P C Huang, S N Stacey, J R Arrand.   

Abstract

Patients suffering from nasopharyngeal carcinoma (NPC) generally exhibit elevated serum IgA antibody titres to Epstein-Barr virus (EBV) early antigen (EA) and virus capsid antigen (VCA). This property is frequently used as a diagnostic aid. Preliminary experiments suggested that an ELISA for IgA antibodies against the EBV-encoded thymidine kinase (TK) could form the basis of a more reliable diagnostic test. Here, we describe the construction of a recombinant baculovirus that expresses the EBV TK and present a full analysis of its use in serological surveys of NPC patients. Baculovirus-derived TK was used to develop a simple ELISA for serum IgA against this antigen. ELISA reactivity was strongly associated with NPC compared with an EBV-positive, normal control population. Comparison with the existing IgA-VCA and EA assays showed that the TK ELISA had higher sensitivity whilst the specificity was similar or higher. We conclude that the TK ELISA presents a strong predictor of NPC and, in its refined form, has improved pickup rates. In addition, results from patients with chronic nasopharyngitis (CNP) suggest that individuals with both symptoms of CNP and an elevated TK ELISA value may be at increased risk for the development of head-and-neck cancer. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11267982     DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1108>3.0.co;2-g

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.

Authors:  Allan Hildesheim; Denise L Doolan; Anna E Coghill; Ruth M Pfeiffer; Carla Proietti; Wan-Lun Hsu; Yin-Chu Chien; Lea Lekieffre; Lutz Krause; Andy Teng; Jocelyn Pablo; Kelly J Yu; Pei-Jen Lou; Cheng-Ping Wang; Zhiwei Liu; Chien-Jen Chen; Jaap Middeldorp; Jason Mulvenna; Jeff Bethony
Journal:  Clin Cancer Res       Date:  2018-01-04       Impact factor: 12.531

2.  Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.

Authors:  J Fachiroh; D K Paramita; B Hariwiyanto; A Harijadi; H L Dahlia; S R Indrasari; H Kusumo; Y S Zeng; T Schouten; S Mubarika; J M Middeldorp
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

3.  Tumor Microbiome in Nasopharyngeal Carcinoma and Its Association With Prognosis.

Authors:  Guihua Zhong; Wei Wei; Wei Liao; Rong Wang; Yingpeng Peng; Yuling Zhou; Xiaotao Huang; Shiping Xian; Shunli Peng; Zhaoyuan Zhang; Shaoyan Feng; Ye Liu; Haiyu Hong; Yunfei Xia; Yan Yan; Qiaodan Liu; Zhigang Liu
Journal:  Front Oncol       Date:  2022-05-23       Impact factor: 5.738

4.  Novel ELISA for serodiagnosis of nasopharyngeal carcinoma based on a B cell epitope of Epstein-Barr virus latent membrane protein 2.

Authors:  Yiqi Cai; Yiling Song; Danwei Cen; Chanqiong Zhang; Shanshan Mao; Xiaoxian Ye; Yirong Xiong; Pengfei Jiang; Jun Chen; Xiangyang Xue; Lifang Zhang; Guanbao Zhu
Journal:  Oncol Lett       Date:  2018-07-25       Impact factor: 2.967

5.  Establishment and validation of a two-step screening scheme for improved performance of serological screening of nasopharyngeal carcinoma.

Authors:  Tingdong Li; Xiaoyi Guo; Mingfang Ji; Fugui Li; Han Wang; Weimin Cheng; Honglin Chen; Munhon Ng; Shengxiang Ge; Yong Yuan; Ningshao Xia
Journal:  Cancer Med       Date:  2018-02-25       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.